Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical device company MAKO Surgical (Nasdaq: MAKO) has earned a respected four-star ranking.

With that in mind, let's take a closer look at MAKO's business and see what CAPS investors are saying about the stock right now.

MAKO facts

Headquarters (Founded) Fort Lauderdale, Fla. (2004)
Market Cap $1.04 billion
Industry Health-care equipment
Trailing-12-Month Revenue $66.4 million
Management Chairman/CEO Maurice Ferre
CFO Fritz LaPorte
Return on Equity (Average, Past 3 Years) (48.1%)
Cash/Debt $50.5 million / $0
Competitors Smith & Nephew (NYSE: SNN)
Stryker (NYSE: SYK)
Zimmer Holdings (NYSE: ZMH)

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96% of the 551 members who have rated MAKO believe the stock will outperform the S&P 500 going forward. These bulls include MajorBob04 and WilliamCrook2003.   

Earlier this week, MajorBob04 tapped MAKO as a solid turnaround opportunity: "Stock price will make a comeback as sales pick up again and margins improve."

Over the next five years, in fact, MAKO is expected to grow its bottom line at a brisk rate of 20% annually. That's much faster than listed rivals Smith & Nephew (7%), Stryker (11%), and Zimmer (9%).

CAPS member WilliamCrook2003 elaborates on the MAKO bull case:

I see a great deal of growth potential in this company, this is evident in as much as this is the fastest growing tech company in the USA [according to Deloitte's Technology Fast 500]. I believe the share price reduction of late is a great opportunity for me to add shares of this company to my real live portfolio. ... I believe in the very near future [MAKO] will become profitable and the share price will gradually begin to climb upwards.

What do you think about MAKO, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. The Motley Fool owns shares of MAKO and Zimmer. Motley Fool newsletter services have recommended buying shares of MAKO and Stryker. Try any of our Foolish newsletter services free for 30 days

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.